Genenta Science (NASDAQ:GNTA – Get Free Report) and Dyadic International (NASDAQ:DYAI – Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership.
Risk and Volatility
Genenta Science has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Dyadic International has a beta of 0.72, meaning that its stock price is 28% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Genenta Science and Dyadic International, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genenta Science | 0 | 0 | 1 | 0 | 3.00 |
| Dyadic International | 0 | 0 | 1 | 0 | 3.00 |
Valuation and Earnings
This table compares Genenta Science and Dyadic International”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genenta Science | N/A | N/A | -$12.60 million | N/A | N/A |
| Dyadic International | $2.90 million | 19.49 | -$6.80 million | ($0.23) | -8.30 |
Dyadic International has higher revenue and earnings than Genenta Science.
Institutional & Insider Ownership
15.1% of Genenta Science shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 29.0% of Genenta Science shares are held by company insiders. Comparatively, 28.8% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Genenta Science and Dyadic International’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Genenta Science | N/A | N/A | N/A |
| Dyadic International | -188.09% | -149.16% | -59.81% |
Summary
Genenta Science beats Dyadic International on 6 of the 9 factors compared between the two stocks.
About Genenta Science
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
About Dyadic International
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.
